What is the role of pharmacotherapy in tobacco cessation in patients with schizophrenia?
Bibliographic record
Abstract
Tobacco use is the leading preventable cause of death and disease in our society, and the prevalence of smoking in individuals with schizophrenia is significantly higher than in the general population (up to 88; v. 20%). Additionally, the risk of cancer in individuals with schizophrenia is increased. In patients with weight gain and diabetes associated with atypical antipsychotic drug use, the risk of cardiovascular death may be further increased. Forced abstinence from nicotine is associated with significant adverse outcomes and is contraindicated in this population. Nicotine replacement therapy (NRT) should be routinely offered to individuals who wish to quit smoking. NRT appears to be both safe and indeed imperative for successful outcomes in tobacco cessation treatment of patients with schizophrenia. The combination of nicotine transdermal patches and nicotine polacrilex gum is advised. Although patients are generally discouraged from smoking while using NRT, cautiously allowing this practice appears to keep them engaged in the process, and the dangers may be overrated. Care should, however, be exercised in the dosing protocol of NRT, assuring adequate nicotinic receptor saturation, with the possibility of cautiously exceeding labelled indications (dose and duration) for heavy smokers. Bupropion is thought to be safe and effective in individuals with schizophrenia and, with adequate blood pressure monitoring, could be combined with NRT. Higher doses of bupropion should be used with caution because of the quite frequent existence of a genetic polymorphism for cytochrome P450 2B6 (CYP2B6). Slow metabolizers of bupropion may have high circulating blood levels, further lowering the seizure threshold when combined with clozapine, necessitating adequate seizure prophylaxis (e.g., divalproex sodium). The use of clozapine (to ameliorate mesolimbic dopaminergic dysregulation) has been associated with a reduction in smoking, whereas the use of typical antipsychotics has been associated with increases in smoking behaviour. The combined use of NRT and atypical antipsychotics appears to be superior to typical antipsychotics combined with NRT in smoking cessation trials in combination with psychosocial interventions. Polynuclear aromatic hydrocarbons in cigarette smoke induce cytochrome P450 1A2 (CYP1A2), which is partially responsible for the metabolism of clozapine, olanzapine and quetiapine. Smoking cessation may interfere with metabolism in that CYP1A2 induction may be reversed, leading to increased bioavailability and higher (and even toxic) plasma levels of clozapine and olanzapine. Neither nicotine (metabolized by CYP2A6) nor bupropion (metabolized by CYP2B6) is expected to alter the pharmacokinetics of each other or of the atypical antipsychotics. Individuals with schizophrenia and tobacco dependence should be offered intensive multimodal treatment, including NRT at adequate doses of optimal duration and, in selected individuals, bupropion. Caution should be exercised to avoid the development of toxic levels of olanzapine or clozapine in patients who quit smoking or manage to reduce their consumption (below 10 cigarettes/d). Pharmacologic and nonpharmacologic interventions, including advocacy for a smoke-free environment, should form part of an intensive multimodal treatment plan, with special attention to compliance. Charl Els, MB ChB, MMed (Psych) Department of Psychiatry University of Alberta Edmonton, Alta.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".